HOW TO USE PCA3:
When the initial biopsy is negative, and a second biopsy is contemplated, a high PCA3 score suggests that cancer has been missed. A second biopsy should be performed.
A low PCA score does not indicate that there is no underlying tumor. A low PCA3 score means it is less likely that a tumor will be found on a subsequent biopsy.
PCA3-D is a genetic-based analysis for prostate cancer detection. This assay identifies abnormally high expression of prostate cancer gene 3. PCA3-D analysis yields a higher specificity than traditional PSA testing.
PCA3-D performed at OURLab helps predict the presence of cancer within contemporaneously obtained prostate biopsies.
PCA3-D is a urine based test that is less invasive than a second biopsy and reduces the need to obtain that biopsy when both the PCA3 value and clinical suspicion is low. It can predict the likelihood of cancer being present within an individual biopsy.
OURLab quantifies the ratio of the PCA-3 mRNA to PSA mRNA in the prostatic cells. The higher the ratio, the higher the risk of malignant diagnosis on a biopsy or repeat biopsy
